{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Drug resistance", "Lung cancer", "Polymorphisms", "lncRNAs", "miRNAs"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "37829813", "DateRevised": {"Year": "2023", "Month": "10", "Day": "31"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "10", "Day": "04"}], "Language": ["eng"], "ELocationID": ["e20652", "10.1016/j.heliyon.2023.e20652"], "Journal": {"ISSN": "2405-8440", "JournalIssue": {"Volume": "9", "Issue": "10", "PubDate": {"Year": "2023", "Month": "Oct"}}, "Title": "Heliyon", "ISOAbbreviation": "Heliyon"}, "ArticleTitle": "The crosstalk between non-coding RNA polymorphisms and resistance to lung cancer therapies.", "Pagination": {"StartPage": "e20652", "MedlinePgn": "e20652"}, "Abstract": {"AbstractText": ["Lung cancer (LC) is one of the most common cancer-related mortality in the world. Even with intensive multimodality therapies, lung cancer has a poor prognosis and a high morbidity rate. This review focused on the role of non-coding RNA polymorphisms such as lncRNAs and miRNAs in the resistance to LC therapies, which could open promising avenue for better therapeutic response. Of note, there is currently no valid biomarker to predict lung cancer sensitivity in patients during treatment. Since genetic variations cause many challenges in treating patients, genotyping of known polymorphisms must be thoroughly explored to find desirable treatment platforms. With this knowledge, individualized treatments could become more possible in management of LC."], "CopyrightInformation": "\u00a9 2023 The Authors."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Natural Products and Medicinal Plants Research Center, North Khorasan University of Medical Sciences, Bojnurd, Iran."}], "LastName": "Mollazadeh", "ForeName": "Samaneh", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Advanced Sciences and Technologies, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran."}], "LastName": "Abdolahzadeh", "ForeName": "Negar", "Initials": "N"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Medical Genetics and Molecular Medicine Department, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran."}], "LastName": "Moghbeli", "ForeName": "Meysam", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Medical Genetics and Molecular Medicine Department, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran."}], "LastName": "Arab", "ForeName": "Fatemeh", "Initials": "F"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Medical Genetics and Molecular Medicine Department, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran."}, {"Identifier": [], "Affiliation": "Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran."}], "LastName": "Saburi", "ForeName": "Ehsan", "Initials": "E"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Heliyon", "NlmUniqueID": "101672560", "ISSNLinking": "2405-8440"}, "CoiStatement": "The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Bray F., et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018;68(6):394\u2013424.", "ArticleIdList": ["30207593"]}, {"Citation": "https://gco.iarc.fr/today/fact-sheets-cancers"}, {"Citation": "Siegel R.L., Miller K.D., Jemal A. Cancer statistics. CA Cancer J Clin, 2020. 2020;70(1):7\u201330.", "ArticleIdList": ["31912902"]}, {"Citation": "Linda M.O.K., et al. Smoking as a risk factor for lung cancer in women and men: a systematic review and meta-analysis. BMJ Open. 2018;8(10)", "ArticleIdList": ["PMC6194454", "30287668"]}, {"Citation": "Minichilli F., et al. Risk factors for lung cancer in the Province of Lecce: results from the PROTOS Case\u2013control study in Salento (Southern Italy) Int. J. Environ. Res. Publ. Health. 2022;19(14):8775.", "ArticleIdList": ["PMC9324751", "35886627"]}, {"Citation": "Ullah A., et al. Clinicopathological and treatment patterns of combined small-cell lung carcinoma with future insight to treatment: a population-based study. J. Clin. Med. 2023;12 doi: 10.3390/jcm12030991.", "ArticleIdList": ["10.3390/jcm12030991", "PMC9918142", "36769639"]}, {"Citation": "https://www.ncbi.nlm.nih.gov/books/NBK482458/"}, {"Citation": "Siegel R.L., Miller K.D., Jemal A. Cancer statistics. CA Cancer J Clin, 2019. 2019;69(1):7\u201334.", "ArticleIdList": ["30620402"]}, {"Citation": "Almquist D., Mosalpuria K., Ganti A.K. Multimodality therapy for limited-stage small-cell lung cancer. Journal of oncology practice. 2016;12(2):111\u2013117.", "ArticleIdList": ["26869647"]}, {"Citation": "Wang Y., et al. New insights into small\u2010cell lung cancer development and therapy. Cell Biol. Int. 2020;44(8):1564\u20131576.", "ArticleIdList": ["PMC7496722", "32281704"]}, {"Citation": "McMullen S., et al. Treatment decisions for advanced non-squamous non-small cell lung cancer: patient and physician perspectives on maintenance therapy. The Patient-Patient-Centered Outcomes Research. 2019;12:223\u2013233.", "ArticleIdList": ["PMC6397138", "30128728"]}, {"Citation": "Abbas Z., Rehman S. An overview of cancer treatment modalities. Neoplasm. 2018;1:139\u2013157."}, {"Citation": "Elmore L.W., et al. Blueprint for cancer research: critical gaps and opportunities. CA A Cancer J. Clin. 2021;71(2):107\u2013139.", "ArticleIdList": ["33326126"]}, {"Citation": "Esfahani K., et al. A review of cancer immunotherapy: from the past, to the present, to the future. Curr. Oncol. 2020;27(s2):87\u201397.", "ArticleIdList": ["PMC7194005", "32368178"]}, {"Citation": "Yu S., et al. Effective combinations of immunotherapy and radiotherapy for cancer treatment. Front. Oncol. 2022;12:231.", "ArticleIdList": ["PMC8858950", "35198442"]}, {"Citation": "Bayat Mokhtari R., et al. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022\u201338043.", "ArticleIdList": ["PMC5514969", "28410237"]}, {"Citation": "Wang K., Tepper J.E. Radiation therapy\u2010associated toxicity: Etiology, management, and prevention. CA A Cancer J. Clin. 2021;71(5):437\u2013454.", "ArticleIdList": ["34255347"]}, {"Citation": "Wirsd\u00f6rfer F., De Leve S., Jendrossek V. Combining radiotherapy and immunotherapy in lung cancer: can we expect limitations due to altered normal tissue toxicity? Int. J. Mol. Sci. 2018;20(1):24.", "ArticleIdList": ["PMC6337556", "30577587"]}, {"Citation": "Meng L., et al. The combination of radiotherapy with immunotherapy and potential predictive biomarkers for treatment of non-small cell lung cancer patients. Front. Immunol. 2021;12", "ArticleIdList": ["PMC8490639", "34621270"]}, {"Citation": "Gummadi A.C., Guddati A.K. Genetic polymorphisms in pharmaceuticals and chemotherapy. World J. Oncol. 2021;12(5):149.", "ArticleIdList": ["PMC8577603", "34804277"]}, {"Citation": "Karki R., et al. Defining \u201cmutation\u201d and \u201cpolymorphism\u201d in the era of personal genomics. BMC Med. Genom. 2015;8:1\u20137.", "ArticleIdList": ["PMC4502642", "26173390"]}, {"Citation": "Aga S.S., Banday M.Z., Nissar S. CRC Press; 2022. Genetic Polymorphism and Disease."}, {"Citation": "Kocal G.C., Baskin Y. Polymorphisms in pharmacogenetics of personalized cancer therapy. Genetic Polymorphisms. 2017;1"}, {"Citation": "Robert F., Pelletier J. Exploring the impact of single-nucleotide polymorphisms on translation. Front. Genet. 2018;9:507.", "ArticleIdList": ["PMC6218417", "30425729"]}, {"Citation": "Milad M., et al. bioRxiv; 2021. Polymorphic SNPs, Short Tandem Repeats and Structural Variants Are Responsible for Differential Gene Expression across C57BL/6 and C57BL/10 Substrains; p. 2020. 03.16.993683.", "ArticleIdList": ["PMC9205302", "35720252"]}, {"Citation": "van Arensbergen J., et al. High-throughput identification of human SNPs affecting regulatory element activity. Nat. Genet. 2019;51(7):1160\u20131169.", "ArticleIdList": ["PMC6609452", "31253979"]}, {"Citation": "Arensbergen J.v., et al. bioRxiv; 2018. Systematic Identification of Human SNPs Affecting Regulatory Element Activity."}, {"Citation": "Franczyk B., Rysz J. A. Gluba-brz\u00f3zka pharmacogenetics of drugs used in the treatment of cancers. Genes. 2022;13 doi: 10.3390/genes13020311.", "ArticleIdList": ["10.3390/genes13020311", "PMC8871547", "35205356"]}, {"Citation": "Ahmed S., et al. Pharmacogenomics of drug metabolizing enzymes and transporters: relevance to precision medicine. Dev. Reprod. Biol. 2016;14(5):298\u2013313.", "ArticleIdList": ["PMC5093856", "27729266"]}, {"Citation": "Lauschke V.M., Milani L., Ingelman-Sundberg M. Pharmacogenomic biomarkers for improved drug therapy\u2014recent progress and future developments. AAPS J. 2017;20(1):4.", "ArticleIdList": ["29181807"]}, {"Citation": "Zhao T. 243P the effects of genomic polymorphisms in one-carbon metabolism pathways on survival of gastric cancer patients received fluorouracil-based adjuvant therapy. Ann. Oncol. 2016;27:ix76.", "ArticleIdList": ["PMC4960563", "27456431"]}, {"Citation": "Colvin L.A. Chemotherapy-induced peripheral neuropathy (CIPN): where are we now? Pain. 2019;160(Suppl 1):S1.", "ArticleIdList": ["PMC6499732", "31008843"]}, {"Citation": "Pathania S., et al. Drug metabolizing enzymes and their inhibitors' role in cancer resistance. Biomed. Pharmacother. 2018;105:53\u201365.", "ArticleIdList": ["29843045"]}, {"Citation": "Wang H., et al. Association analysis of CYP2A6 genotypes and haplotypes with 5-fluorouracil formation from tegafur in human liver microsomes. Pharmacogenomics. 2011;12(4):481\u2013492.", "ArticleIdList": ["21521021"]}, {"Citation": "Bertholee D., Maring J.G., van Kuilenburg A.B. Genotypes affecting the pharmacokinetics of anticancer drugs. Clin. Pharmacokinet. 2017;56(4):317\u2013337.", "ArticleIdList": ["PMC5340837", "27641154"]}, {"Citation": "Cao J., et al. Non-coding RNA in thyroid cancer-Functions and mechanisms. Cancer Lett. 2021;496:117\u2013126.", "ArticleIdList": ["32949678"]}, {"Citation": "Gou L.-T., Zhu Q., Liu M.-F. Fundamental Research; 2023. Small RNAs: an Expanding World with Therapeutic Promises."}, {"Citation": "Slack F.J., Chinnaiyan A.M. The role of non-coding RNAs in oncology. Cell. 2019;179(5):1033\u20131055.", "ArticleIdList": ["PMC7347159", "31730848"]}, {"Citation": "Wang K.C., et al. A long noncoding RNA maintains active chromatin to coordinate homeotic gene expression. Nature. 2011;472(7341):120\u2013124.", "ArticleIdList": ["PMC3670758", "21423168"]}, {"Citation": "Engreitz J.M., Ollikainen N., Guttman M. Long non-coding RNAs: spatial amplifiers that control nuclear structure and gene expression. Nat. Rev. Mol. Cell Biol. 2016;17(12):756\u2013770.", "ArticleIdList": ["27780979"]}, {"Citation": "Gao N., et al. Long non-coding RNAs: the regulatory mechanisms, research strategies, and future directions in cancers. Front. Oncol. 2020;10", "ArticleIdList": ["PMC7775490", "33392092"]}, {"Citation": "Beermann J., et al. Non-coding RNAs in development and disease: Background, mechanisms, and therapeutic approaches. Physiol. Rev. 2016;96(4):1297\u20131325.", "ArticleIdList": ["27535639"]}, {"Citation": "Zhao J., et al. Polycomb proteins targeted by a short repeat RNA to the mouse X chromosome. Science. 2008;322(5902):750\u2013756.", "ArticleIdList": ["PMC2748911", "18974356"]}, {"Citation": "Jiang C., et al. Long non-coding RNAs: potential new biomarkers for predicting tumor invasion and metastasis. Mol. Cancer. 2016;15(1):62.", "ArticleIdList": ["PMC5043609", "27686732"]}, {"Citation": "Ji P., et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene. 2003;22(39):8031\u20138041.", "ArticleIdList": ["12970751"]}, {"Citation": "Cabili M.N., et al. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev. 2011;25(18):1915\u20131927.", "ArticleIdList": ["PMC3185964", "21890647"]}, {"Citation": "Necsulea A., et al. The evolution of lncRNA repertoires and expression patterns in tetrapods. Nature. 2014;505(7485):635\u2013640.", "ArticleIdList": ["24463510"]}, {"Citation": "Ye R., et al. New insights into long non-coding RNAs in non-small cell lung cancer. Biomed. Pharmacother. 2020;131", "ArticleIdList": ["33152934"]}, {"Citation": "Zangouei A.S., et al. Cell cycle related long non-coding RNAs as the critical regulators of breast cancer progression and metastasis. Biol. Res. 2023;56(1):1.", "ArticleIdList": ["PMC9808980", "36597150"]}, {"Citation": "Akhlaghipour I., et al. MicroRNA-377: a therapeutic and diagnostic tumor marker. Int. J. Biol. Macromol. 2023;226:1226\u20131235.", "ArticleIdList": ["36442575"]}, {"Citation": "Jiang J., et al. The Emerging roles of long noncoding RNAs as Hallmarks of lung cancer. Front. Oncol. 2021;11", "ArticleIdList": ["PMC8529012", "34692550"]}, {"Citation": "Hussenet T., et al. SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLoS One. 2010;5(1):e8960.", "ArticleIdList": ["PMC2813300", "20126410"]}, {"Citation": "Sholl L.M., et al. Sox2 protein expression is an independent poor prognostic indicator in stage I lung adenocarcinoma. Am. J. Surg. Pathol. 2010;34(8):1193\u20131198.", "ArticleIdList": ["PMC2923819", "20631605"]}, {"Citation": "Ying J., et al. Expression and significance of SOX2 in non-small cell lung carcinoma. Oncol. Lett. 2016;12(5):3195\u20133198.", "ArticleIdList": ["PMC5103921", "27899982"]}, {"Citation": "Liu X.-Y., et al. The role of circular RNAs in the drug resistance of cancers. Front. Oncol. 2022;11", "ArticleIdList": ["PMC8766647", "35070998"]}, {"Citation": "Herrera\u2010Solorio A.M., et al. LncRNA SOX2\u2010OT regulates AKT/ERK and SOX2/GLI\u20101 expression, hinders therapy, and worsens clinical prognosis in malignant lung diseases. Mol. Oncol. 2021;15(4):1110\u20131129.", "ArticleIdList": ["PMC8024737", "33433063"]}, {"Citation": "Gong WJ, Peng JB, Yin JY, Li XP, Zheng W, Xiao L, Tan LM, Xiao D, Chen YX, Li X, Zhou HH, Liu ZQ. Association between well-characterized lung cancer lncRNA polymorphisms and platinum-based chemotherapy toxicity in Chinese patients with lung cancer. Acta Pharmacol Sin. 2017 Apr;38(4):581\u2013590.", "ArticleIdList": ["PMC5386317", "28260796"]}, {"Citation": "Huang D., et al. NKILA lncRNA promotes tumor immune evasion by sensitizing T cells to activation-induced cell death. Nat. Immunol. 2018;19(10):1112\u20131125.", "ArticleIdList": ["30224822"]}, {"Citation": "Sun Y., et al. Long non-coding RNA HOTTIP promotes BCL-2 expression and induces chemoresistance in small cell lung cancer by sponging miR-216a. Cell Death Dis. 2018;9(2):85.", "ArticleIdList": ["PMC5833383", "29367594"]}, {"Citation": "Zeng F., et al. Linc00173 promotes chemoresistance and progression of small cell lung cancer by sponging miR-218 to regulate Etk expression. Oncogene. 2020;39(2):293\u2013307.", "ArticleIdList": ["31477834"]}, {"Citation": "Zhang Z., et al. Role of long non-coding RNA polymorphisms in cancer chemotherapeutic response. J. Personalized Med. 2021;11 doi: 10.3390/jpm11060513.", "ArticleIdList": ["10.3390/jpm11060513", "PMC8228201", "34199840"]}, {"Citation": "Hu L., et al. Clinical significance of long non-coding RNA CASC8 rs10505477 polymorphism in lung cancer susceptibility, platinum-based chemotherapy response, and toxicity. Int. J. Environ. Res. Publ. Health. 2016;13(6):545.", "ArticleIdList": ["PMC4924002", "27249003"]}, {"Citation": "Dorraki N., et al. miRNA-148b and its role in various cancers. Epigenomics. 2021;13(24):1939\u20131960.", "ArticleIdList": ["34852637"]}, {"Citation": "Shapouri-Moghaddam A., et al. Cardioprotective microRNAs: Lessons from stem cell-derived exosomal microRNAs to treat cardiovascular disease. Atherosclerosis. 2019;285:1\u20139.", "ArticleIdList": ["30939341"]}, {"Citation": "Zhong S., et al. miRNAs in lung cancer. A systematic review identifies predictive and prognostic miRNA candidates for precision medicine in lung cancer. Transl. Res. 2021;230:164\u2013196.", "ArticleIdList": ["33253979"]}, {"Citation": "Pratama M.Y., et al. Circulatory miRNA as a biomarker for therapy response and disease-free survival in Hepatocellular carcinoma. Cancers. 2020;12(10)", "ArticleIdList": ["PMC7601056", "33003646"]}, {"Citation": "Bukowski K., Kciuk M., Kontek R. Mechanisms of multidrug resistance in cancer chemotherapy. Int. J. Mol. Sci. 2020;21(9):3233.", "ArticleIdList": ["PMC7247559", "32370233"]}, {"Citation": "Ma X., Liang A.L., Liu Y.J. Research progress on the relationship between lung cancer drug-resistance and microRNAs. J. Cancer. 2019;10(27):6865\u20136875.", "ArticleIdList": ["PMC6909942", "31839821"]}, {"Citation": "Li G., et al. MiRNA-based therapeutic Strategy in lung cancer. Curr Pharm Des. 2018;23(39):6011\u20136018.", "ArticleIdList": ["28745212"]}, {"Citation": "Costantini A., et al. Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab. OncoImmunology. 2018;7(8)", "ArticleIdList": ["PMC6136870", "30221046"]}, {"Citation": "Fan J., et al. Circulating microRNAs predict the response to anti-PD-1 therapy in non-small cell lung cancer. Genomics. 2020;112(2):2063\u20132071.", "ArticleIdList": ["31786291"]}, {"Citation": "Zhang H., et al. miR-181c contributes to cisplatin resistance in non-small cell lung cancer cells by targeting Wnt inhibition factor 1. Cancer Chemother. Pharmacol. 2017;80(5):973\u2013984.", "ArticleIdList": ["28956120"]}, {"Citation": "Liu H., et al. miR-7 modulates chemoresistance of small cell lung cancer by repressing MRP1/ABCC1. Int. J. Exp. Pathol. 2015;96(4):240\u2013247.", "ArticleIdList": ["PMC4561560", "26108539"]}, {"Citation": "Li B., et al. MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer. Lung Cancer. 2014;83(2):146\u2013153.", "ArticleIdList": ["24331411"]}, {"Citation": "Lin L., et al. MicroRNA-21 regulates non-small cell lung cancer cell invasion and chemo-sensitivity through SMAD7. Cell. Physiol. Biochem. 2016;38(6):2152\u20132162.", "ArticleIdList": ["27185036"]}, {"Citation": "Jiang S., et al. MicroRNA-21 modulates radiation resistance through upregulation of hypoxia-inducible factor-1\u03b1-promoted glycolysis in non-small cell lung cancer cells. Mol. Med. Rep. 2016;13(5):4101\u20134107.", "ArticleIdList": ["27035555"]}, {"Citation": "Garofalo M., et al. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med. 2011;18(1):74\u201382.", "ArticleIdList": ["PMC3467100", "22157681"]}, {"Citation": "Kitamura K., et al. MiR-134/487b/655 cluster regulates TGF-\u03b2-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells. Mol Cancer Ther. 2014;13(2):444\u2013453.", "ArticleIdList": ["24258346"]}, {"Citation": "Rzeszowska-Wolny J., et al. Involvement of miRNAs in cellular responses to radiation. Int. J. Radiat. Biol. 2022;98(3):479\u2013488.", "ArticleIdList": ["35030053"]}, {"Citation": "Chen Y., et al. MicroRNA: a novel implication for damage and protection against ionizing radiation. Environ. Sci. Pollut. Control Ser. 2021;28:15584\u201315596.", "ArticleIdList": ["PMC7854028", "33533004"]}, {"Citation": "Soares S., et al. The influence of miRNAs on radiotherapy treatment in Prostate cancer \u2013 a systematic review. Front. Oncol. 2021:11.", "ArticleIdList": ["PMC8369466", "34414113"]}, {"Citation": "Tang Y., et al. Radiation-induced miR-208a increases the proliferation and radioresistance by targeting p21 in human lung cancer cells. J. Exp. Clin. Cancer Res. 2016;35:7.", "ArticleIdList": ["PMC4710038", "26754670"]}, {"Citation": "He Z., et al. miR-25 modulates NSCLC cell radio-sensitivity through directly inhibiting BTG2 expression. Biochem. Biophys. Res. Commun. 2015;457(3):235\u2013241.", "ArticleIdList": ["25576360"]}, {"Citation": "Li Y., et al. Knockdown of microRNA-1323 restores sensitivity to radiation by suppression of PRKDC activity in radiation-resistant lung cancer cells. Oncol. Rep. 2015;33(6):2821\u20132828.", "ArticleIdList": ["25823795"]}, {"Citation": "Fang C., et al. Functional miRNA variants affect lung cancer susceptibility and platinum-based chemotherapy response. J. Thorac. Dis. 2018;10(6):3329\u20133340.", "ArticleIdList": ["PMC6051820", "30069329"]}, {"Citation": "Yip P.Y. Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer. Transl. Lung Cancer Res. 2015;4(2):165\u2013176.", "ArticleIdList": ["PMC4384220", "25870799"]}, {"Citation": "Jiang W., et al. MicroRNA-related polymorphisms in PI3K/Akt/mTOR pathway genes are predictive of limited-disease small cell lung cancer treatment outcomes. BioMed Res. Int. 2017;2017", "ArticleIdList": ["PMC5322445", "28280736"]}, {"Citation": "Amjad M.T., Chidharla A., Kasi A. StatPearls2022, StatPearls PublishingCopyright \u00a9. StatPearls Publishing LLC; Treasure Island (FL: 2022. Cancer chemotherapy."}, {"Citation": "Wardell C.P., et al. Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations. J. Hepatol. 2018;68(5):959\u2013969.", "ArticleIdList": ["29360550"]}, {"Citation": "Auwerx C., et al. From pharmacogenetics to pharmaco-omics: Milestones and future directions. HGG Adv. 2022;3(2)", "ArticleIdList": ["PMC8971318", "35373152"]}, {"Citation": "Miteva-Marcheva N.N., et al. Application of pharmacogenetics in oncology. Biomark. Res. 2020;8(1):32.", "ArticleIdList": ["PMC7429778", "32821392"]}], "ReferenceList": []}], "History": [{"Year": "2023", "Month": "4", "Day": "3"}, {"Year": "2023", "Month": "9", "Day": "23"}, {"Year": "2023", "Month": "10", "Day": "3"}, {"Year": "2023", "Month": "10", "Day": "13", "Hour": "6", "Minute": "46"}, {"Year": "2023", "Month": "10", "Day": "13", "Hour": "6", "Minute": "45"}, {"Year": "2023", "Month": "10", "Day": "13", "Hour": "4", "Minute": "12"}, {"Year": "2023", "Month": "10", "Day": "4"}], "PublicationStatus": "epublish", "ArticleIdList": ["37829813", "PMC10565774", "10.1016/j.heliyon.2023.e20652", "S2405-8440(23)07860-X"]}}], "PubmedBookArticle": []}